|
|
R&D Portfolio
By December 2011, there are 60 projects and vaccines under clinical development including 17 in phase 3 or submitted to healthcare authorities in the R&D portfolio of Sanofi.
An ever-changing portfolio
Sanofi submitted five products to regulatory authorities in the U.S. and/or in EU during the 2nd semester: - Kynamro™ (mipomersen), in the EU for the treatment of familial hypercholesterolemia
- Aubagio™ (teriflunomide), in the U.S.for the treatment of relapsing multiple sclerosis.
- Visamerin® / Mulsevo® (semuloparin), in the EU and U.S. for the prevention of VenoThrombo-Embolism events in cancer patients initiating a chemotherapy regimen.
- Lyxumia® (lixisenatide), in the EU for the treatment of types 2 diabetes.
- Zaltrap® (aflibercept), in the EU for the treatment of metastatic colorectal cancer
For the marketed products, the pediatric file for Lantus® has been submitted in the EU. Since the last quarterly R&D update, the evolution of the R&D portfolio has been favourable with additional positive Phase III results for Lemtrada™ (alemtuzumab), Lyxumia® (lixisenatide) and Aubagio™ (teriflunomide); the beginning of a Phase III program for a new formulation of insulin glargine and for a JAK-2 inhibitor; the entry into Phase II of 5 compounds.
All projects in late phases of development
All projects in early phases of clinical development
Genzyme's R&D portfolio
The takeover of Genzyme has reinforced our position in biological products and the treatment of rare diseases. Our portfolio has thus been enriched by 11 new molecular entities, including three short-term opportunities: alemtuzumab for multiple sclerosis, mipomersen for familial hypercholesterolemia and eliglustat for Gaucher disease, etc.
|
Further information
Genzyme R&D portfolio
Corporate events
February 8, 2012
|
